ADDvise Group AB (publ) - Rights Issue of approximately SEK 24.9 million is oversubscribed – Regulatory information

05-02-2019   Regulatory press release

ADDvise Group AB (publ) (”ADDvise” or the “Company”) has completed the rights issue of 43 042 288 units that was published December 12th2018 (the ”Rights Issue”). The Rights Issue has been subscribed to a total of 106.1 percent, which approximately 92.3 percent was subscribed for with preferential unit rights and approximately 13.8 percent were subscribed without preferential unit rights. Through the Rights Issue, the Company is allocated approximately SEK 24.9 million before issue costs.

Allotment of units subscribed without preferential unit rights has been made in accordance with the terms stated in the investment memorandum. Notification of such allocation shall be communicated separately by registered settlement note. Nominee registered shareholders receive a notice of allocation in accordance with instructions from the respective trustees.

Through the Rights Issue, ADDvise share capital increases by SEK 4,304,228.80 through the issuance of 43,042,288 shares of series B. Following the rights issue, the share capital in the Company amounts to SEK 8,608,457.60 and the number of shares will amount to 86,084 576 shares after registration with the Swedish Companies Registration Office of the rights issue. In addition, 43,042,288 warrants of series 2019/2021 will be issued entitling the holder to subscribe for one (1) new share of series B. The period of utilization is between January 25 and February 8, 2021. The redemption amount for the warrants will be SEK 0.65. The warrants are considered admitted to trading on Nasdaq First North after registration of the rights issue has been completed with the Swedish Companies Registration Office.

For further information, please contact:

Rikard Akhtarzand, CEO

+46 765-25 90 71

rikard.akhtarzand@addvisegroup.se

www.addvisegroup.se

This information is required for ADDvise Group AB (publ) to disclose under the EU market abuse regulation. The information was submitted by ADDvise for publication on February 5th, 2019 at 15.00 CET.

About ADDvise

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com 

Important information

This press release is not an offer to purchase, subscribe for or otherwise trade in shares, units or other financial instruments in ADDvise. Invitation to concerned persons to subscribe for units in ADDvise is only made through the investment memorandum that ADDvise published on 16 January 2019.

This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada or other country where such action as a whole or in part is subject to legal restrictions.

Neither unit rights, units subscribed for ("BTU"), newly issued shares or warrants have been recommended or approved by any US federal or state securities authority or regulatory authority. No unit rights, BTU, newly issued shares have been registered or will be registered under the United States Securities Act of 1933, as applicable, or in accordance with applicable laws in the United States, Australia, Japan, Canada or in any other country where the Rights Issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a prospectus/investment memorandum is established, registered or that any other measure is undertaken beyond that required by Swedish law.

There is no intention to register any portion of the offer in the United States and the securities issued in the Rights Issue will not be offered to the public in the United States.

This press release may contain certain forward-looking information that reflects ADDvise's current views on future events as well as financial and operational development. Words that are "intended", "come", "judged", "expected", "can", "plan", "appreciate" and other expressions that imply indications or predictions about future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual outcomes may differ substantially from what is stated in forward-looking information. This information, the opinions and the forward-looking statements contained in this press release are valid only on this date and may be amended without notice. ADDvise makes no representations about publishing updates or revisions of forward-looking information, future events or similar circumstances other than the applicable law.

Latest press releases

ADDvise announces preliminary result for 2022 which is stronger than expected

Regulatory

The preliminary result for ADDvise Group for the full year 2022 significantly deviates from what ADDvise Group considers to be current market expectations. [image] The net sales pro forma full year 2022 rolling 12 months amounted to SEK 1,097 million with an adjusted EBITDA pro forma of SEK 241 million. The financial targets for the…

ADDvise receives order worth USD 3.5 million

Regulatory

ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an order from AxisCare Health Logistics Inc, a company distributing equipment and medical supplies to hospitals, clinics, medical offices and medical equipment suppliers. The order is worth approximately USD 3.5 million. The order consists of delivery of the prescription dietary supplemental Folite, developed and manufactured by…

ADDvise receives order worth USD 1.8 million

Regulatory

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Nasser Saeed Al Hajri & Partners Contracting (NHS & Partners), a leading construction contractor in the United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves the detailed design, supply and installation of an ISO 8 and ISO 7…